All sponsors

Genmab $GMAB

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-317
RECRUITING10
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO64%

Delay Index: of 22 active trials registered more than a year ago, 14 have moved their primary completion (readout) date by more than 6 months since first registration (median +34.1 months). See all sponsors →

Open Genmab on the live radar map → 📅 $GMAB readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
EPCORE DLBCL-1
NCT04628494
P3Active, not recruitingDiffuse Large B-cell Lymphoma4832025-10-13 (+28 mo)
Epcoritamab
NCT07226752
P3Active, not recruitingDiffuse Large B-Cell Lymphoma722025-10-13
GEN1042
NCT04083599
P1/2Active, not recruitingMalignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC)3502025-12-30 (+61 mo)
RAINFOL-02
NCT06619236
P3Active, not recruitingPlatinum-resistant Ovarian Cancer5842026-08-18 (-5 mo)
Epcoritamab
NCT05451810
P2Active, not recruitingDiffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma1842027-03 (+19 mo)
EPCORE DLBCL-2
NCT05578976
P3Active, not recruitingDiffuse Large B-Cell Lymphoma9002027-06 (+34 mo)
Acasunlimab
NCT06635824
P3Active, not recruitingPD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC1912027-07-30 (+6 mo)
EPCORE™ NHL-3
NCT04542824
P1/2Active, not recruitingDiffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma782027-09 (+35 mo)
RAINFOL-02
NCT07604766
P3RecruitingPlatinum-resistant Ovarian Cancer822027-09
EPCORE™ NHL-2
NCT04663347
P1/2Active, not recruitingDiffuse Large B-Cell Lymphoma; Follicular Lymphoma5432027-09-30 (+68 mo)
Epcoritamab
NCT05201248
P1/2Active, not recruitingB-Cell Non-Hodgkin Lymphoma492027-10 (+46 mo)
RAINFOL-05
NCT07288177
P2RecruitingNon-small Cell Lung Cancer (NSCLC)2402027-11-22
EPCORE™ CLL-1
NCT04623541
P1/2Active, not recruitingRelapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma1942027-12 (+60 mo)
Petosemtamab
NCT06525220
P3Active, not recruitingHead and Neck Squamous Cell Carcinoma6992028-01
Petosemtamab
NCT06496178
P3Active, not recruitingHead and Neck Squamous Cell Carcinoma6212028-02
EPCORE DLBCL-4
NCT06508658
P3Active, not recruitingDiffuse Large B-Cell Lymphoma3792028-03 (+3 mo)
MCLA-158
NCT03526835
P1/2RecruitingAdvanced/Metastatic Solid Tumors; Colorectal Cancer5602028-05 (+88 mo)
RAINFOL-09
NCT07539311
P2RecruitingGastrointestinal Cancers1602028-09
RAINFOL-04
NCT07225270
P3RecruitingOvarian Cancer; Platinum-sensitive Ovarian Cancer5442028-10
RAINFOL-01
NCT05579366
P1/2RecruitingHigh Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer9522028-12 (+47 mo)
EPCORE™ NHL-1
NCT03625037
P1/2Active, not recruitingDLBCL; High-grade B-cell Lymphoma (HGBCL)6662029-01 (+83 mo)
Petosemtamab
NCT07775287
P3RecruitingColorectal Cancer6002029-03-30
Petosemtamab
NCT07702032
P3RecruitingLeft-sided Colorectal Cancer9602029-07
RAINFOL-03
NCT07166094
P3RecruitingEndometrial Cancer; Recurrent or Progressive Endometrial Cancer6602029-08 (+9 mo)
RAINFOL™-07
NCT07564141
P3RecruitingPlatinum-Sensitive Ovarian Cancer; Ovarian Cancer6882029-12
EPCORE FL-1
NCT05409066
P3Active, not recruitingFollicular Lymphoma (FL)5492029-12
RAINFOL™-10
NCT07859215
P3Not yet recruitingOvarian Cancer6022030-03
Epcoritamab
NCT05283720
P2Active, not recruitingNon-Hodgkin Lymphoma2642032-11 (+41 mo)
EPCORE™FL-2
NCT06191744
P3Active, not recruitingFollicular Lymphoma (FL)10952037-11 (+109 mo)